Stock Analysis on Net
Stock Analysis on Net

Danaher Corp. (NYSE:DHR)

$24.99

Operating Profit Margin
since 2005

Microsoft Excel

Paying user area

Try for free

Danaher Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Calculation

Danaher Corp., operating profit margin, long-term trends, calculation

Microsoft Excel
Operating profit margin = 100 × Operating profit1 ÷ Sales1
Dec 31, 2024 = 100 × ÷
Dec 31, 2023 = 100 × ÷
Dec 31, 2022 = 100 × ÷
Dec 31, 2021 = 100 × ÷
Dec 31, 2020 = 100 × ÷
Dec 31, 2019 = 100 × ÷
Dec 31, 2018 = 100 × ÷
Dec 31, 2017 = 100 × ÷
Dec 31, 2016 = 100 × ÷
Dec 31, 2015 = 100 × ÷
Dec 31, 2014 = 100 × ÷
Dec 31, 2013 = 100 × ÷
Dec 31, 2012 = 100 × ÷
Dec 31, 2011 = 100 × ÷
Dec 31, 2010 = 100 × ÷
Dec 31, 2009 = 100 × ÷
Dec 31, 2008 = 100 × ÷
Dec 31, 2007 = 100 × ÷
Dec 31, 2006 = 100 × ÷
Dec 31, 2005 = 100 × ÷

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).

1 US$ in millions

The financial data reveal several key trends over the observed period. Sales generally exhibit a growth trajectory from 2005 through 2023, rising from 7,985 million USD to a peak of 31,471 million USD in 2022 before declining to 23,875 million USD in 2024. This pattern suggests a strong expansion phase, followed by a noticeable contraction in the latest period.

Operating profit follows a similar but somewhat more volatile trend. It increases substantially from 1,265 million USD in 2005 to a significant peak of 8,688 million USD in 2021. After this peak, there is a sharp decline in operating profit to 5,202 million USD in 2023 and further down to 4,863 million USD in 2024. This indicates that profitability peaked earlier than sales, with a rapid correction thereafter.

The operating profit margin, representing profitability relative to sales, shows an overall upward trend across the years. Starting at 15.84% in 2005, it remains relatively stable around the mid-teens until 2016. From 2016 onwards, a marked increase is observed, reaching an all-time high of 27.61% in 2021. Following this, a decline to 21.77% in 2023 and 20.37% in 2024 occurs, mirroring the reduction in operating profit and sales volume.

These patterns imply that the company experienced a period of strong growth and increasing efficiency or pricing power up to around 2021, achieving higher profit margins. However, in the most recent years, both sales and profitability have receded significantly. The decline in sales coupled with lower operating margins suggests challenges in maintaining profitability levels, potentially due to market conditions, increased costs, or other external factors affecting earnings.

Sales Trend
General growth from 7,985 million USD in 2005 to a peak of 31,471 million USD in 2022, followed by a decrease to 23,875 million USD in 2024.
Operating Profit Trend
Increase from 1,265 million USD in 2005 to a high of 8,688 million USD in 2021, then a notable decline to 4,863 million USD by 2024.
Operating Profit Margin Trend
Relatively stable at mid-teens percentage until 2016, rising to a peak of 27.61% in 2021 before declining to 20.37% in 2024.
Overall Interpretation
Strong growth and profitability improvements over the long term, with a recent reversal indicating potential operational or market challenges affecting both sales and profit margins.

Comparison to Competitors

Danaher Corp., operating profit margin, long-term trends, comparison to competitors

Microsoft Excel
Danaher Corp. AbbVie Inc. Amgen Inc. Gilead Sciences Inc. Regeneron Pharmaceuticals Inc. Thermo Fisher Scientific Inc. Vertex Pharmaceuticals Inc.
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Dec 31, 2012
Dec 31, 2011
Dec 31, 2010
Dec 31, 2009
Dec 31, 2008
Dec 31, 2007
Dec 31, 2006
Dec 31, 2005

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).